Hematology and Cell Therapy Area, Clinica Universidad de Navarra and Division of Cancer, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
PLoS One. 2012;7(8):e43683. doi: 10.1371/journal.pone.0043683. Epub 2012 Aug 31.
Stroke represents an attractive target for stem cell therapy. Although different types of cells have been employed in animal models, a direct comparison between cell sources has not been performed. The aim of our study was to assess the effect of human multipotent adult progenitor cells (hMAPCs) and human mesenchymal stem cells (hMSCs) on endogenous neurogenesis, angiogenesis and inflammation following stroke. BALB/Ca-RAG 2(-/-) γC(-/-) mice subjected to FeCl(3) thrombosis mediated stroke were intracranially injected with 2 × 10(5) hMAPCs or hMSCs 2 days after stroke and followed for up to 28 days. We could not detect long-term engraftment of either cell population. However, in comparison with PBS-treated animals, hMSC and hMAPC grafted animals demonstrated significantly decreased loss of brain tissue. This was associated with increased angiogenesis, diminished inflammation and a glial-scar inhibitory effect. Moreover, enhanced proliferation of cells in the subventricular zone (SVZ) and survival of newly generated neuroblasts was observed. Interestingly, these neuroprotective effects were more pronounced in the group of animals treated with hMAPCs in comparison with hMSCs. Our results establish cell therapy with hMAPCs and hMSCs as a promising strategy for the treatment of stroke.
中风是干细胞治疗的一个有吸引力的靶点。尽管在动物模型中已经使用了不同类型的细胞，但尚未对细胞来源进行直接比较。我们的研究旨在评估人多能成体祖细胞（hMAPC）和人骨髓间充质干细胞（hMSC）对中风后内源性神经发生、血管生成和炎症的影响。在 FeCl3 血栓介导的中风后 2 天，BALB/Ca-RAG 2(-/-)γC(-/-)小鼠通过颅内注射 2×105 hMAPC 或 hMSC，并在 28 天内进行随访。我们无法检测到两种细胞群的长期植入。然而，与 PBS 处理的动物相比，hMSC 和 hMAPC 移植的动物明显减少了脑组织的损失。这与血管生成增加、炎症减轻和胶质瘢痕抑制作用有关。此外，观察到脑室下区（SVZ）的细胞增殖增加和新生成的神经母细胞的存活。有趣的是，与 hMSC 相比，hMAPC 治疗组的这些神经保护作用更为显著。我们的研究结果确立了 hMAPC 和 hMSC 的细胞治疗作为中风治疗的一种有前途的策略。
